TipRanks on MSN
TG Therapeutics price target raised to $15 from $13 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on TG Therapeutics (TGTX) to $15 from $13 and keeps an Underperform rating on the ...
TG Therapeutics is winding down its oncology program after removing the FDA-approved cancer med Ukoniq from the market in two indications that were granted accelerated approval in addition to ...
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback